[A18-37] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 06.12.2018
Project no.:
A18-37
Commission:
Commission awarded on 06.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Treatment-naive adults with advanced renal cell carcinoma (intermediate or poor risk)
Intermediate risk: hint of non-quantifiable added benefit in positive MET IHC status; added benefit not proven in other cases; poor risk: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-18 | Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56 | Commission completed |
| A18-13 | Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56 | Commission completed |
| A17-56 | Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-85 | Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-70 | Cabozantinib (renal cell carcinoma) - Addendum to Commission A18-37 | Commission completed |
| G21-20 | Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| A22-59 | Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-12-06 A G-BA decision was published.